A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Project: Research project

Project Details

StatusActive
Effective start/end date2/14/22 → 2/13/27

Funding

  • GlaxoSmithKline Pharmaceuticals: $10,020.00